Fate Therapeutics Inc.

66.50+1.69+2.61%Vol 707.27K1Y Perf 76.52%
Sep 15th, 2021 16:00 DELAYED
BID66.42 ASK66.50
Open64.63 Previous Close64.81
Pre-Market- After-Market-
 - -%  - -
Target Price
107.20 
Analyst Rating
Strong Buy 1.25
Potential %
61.20 
Finscreener Ranking
★★★★+     55.80
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.33
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     62.31
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
36.26 
Earnings Rating
Sell
Market Cap6.33B 
Earnings Date
4th Nov 2021
Alpha0.05 Standard Deviation0.20
Beta1.62 

Today's Price Range

64.1166.83

52W Range

35.40121.16

5 Year PE Ratio Range

-11.60-3.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.07%
1 Month
-24.11%
3 Months
-19.54%
6 Months
-25.89%
1 Year
76.52%
3 Years
471.80%
5 Years
2 177.40%
10 Years
-

TickerPriceChg.Chg.%
FATE66.501.69002.61
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
6.70
6.80
0.12
0.15
-275.20
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-423.20
-415.40
-936.40
-
RevenueValueIndustryS&P 500US Markets
48.01M
0.50
106.50
56.05
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.52-0.58-11.54
Q01 2021-0.42-0.48-14.29
Q04 2020-0.38-0.380.00
Q03 2020-0.29-0.36-24.14
Q02 2020-0.20-0.35-75.00
Q01 2020-0.38-0.44-15.79
Q04 2019-0.39-0.375.13
Q03 2019-0.38-0.40-5.26
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.58-5.45Negative
12/2021 QR-0.58-7.41Negative
12/2021 FY-2.24-5.16Negative
12/2022 FY-2.60-4.42Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.58
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume707.27K
Shares Outstanding95.19M
Shares Float68.05M
Trades Count11.20K
Dollar Volume116.79M
Avg. Volume1.03M
Avg. Weekly Volume783.55K
Avg. Monthly Volume1.38M
Avg. Quarterly Volume1.01M

Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 66.5 per share at the end of the most recent trading day (a 2.61% change compared to the prior day closing price) with a volume of 713.30K shares and market capitalization of 6.33B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.

The one-year performance of Fate Therapeutics Inc. stock is 76.52%, while year-to-date (YTD) performance is -26.87%. FATE stock has a five-year performance of 2177.4%. Its 52-week range is between 35.4 and 121.16, which gives FATE stock a 52-week price range ratio of 36.26%

Fate Therapeutics Inc. currently has a PE ratio of -29.10, a price-to-book (PB) ratio of 8.66, a price-to-sale (PS) ratio of 130.42, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -24.86%, a ROC of -30.12% and a ROE of -33.86%. The company’s profit margin is -%, its EBITDA margin is -415.40%, and its revenue ttm is $48.01 Million , which makes it $0.50 revenue per share.

Of the last four earnings reports from Fate Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.58 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Strong Buy (1.25), with a target price of $107.2, which is +61.20% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fate Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.56, ATR14 : 4.21, CCI20 : -123.89, Chaikin Money Flow : -0.24, MACD : -4.36, Money Flow Index : 49.05, ROC : -8.45, RSI : 36.47, STOCH (14,3) : 19.55, STOCH RSI : 0.39, UO : 28.17, Williams %R : -80.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $68 250), Bahram Valamehr (Sold 84 484 shares of value $7 500 645 ), Cindy Tahl (Option Excercise at a value of $1 449 141), Cindy Tahl (Sold 474 000 shares of value $32 862 200 ), Daniel D. Shoemaker (Sold 59 482 shares of value $4 429 085 ), Edward J. Dulac (Sold 3 474 shares of value $306 602 ), J. Scott Wolchko (Option Excercise at a value of $1 392 108), J. Scott Wolchko (Sold 389 407 shares of value $34 669 876 ), Yu-Waye Chu (Sold 3 275 shares of value $272 809 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
14 (87.50 %)
15 (88.24 %)
14 (87.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (12.50 %)
2 (11.76 %)
2 (12.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.24
Strong Buy
1.25

Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

CEO: J. Scott Wolchko

Telephone: +1 858 875-1800

Address: 3535 General Atomics Court, San Diego 92121, CA, US

Number of employees: 279

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

55%45%

Bearish Bullish

53%47%

TipRanks News for FATE

Tue, 24 Aug 2021 12:05 GMT Fate Therapeutics (FATE) Gets a Buy Rating from Wells Fargo

- TipRanks. All rights reserved.

News

Stocktwits